Ionis Pharmaceuticals IONS Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's contract liabilities?
- Ionis Pharmaceuticals (IONS) reported contract liabilities of $75.75M in Q1 2026.
- How has Ionis Pharmaceuticals's contract liabilities changed year-over-year?
- Ionis Pharmaceuticals's contract liabilities decreased by 46.2% year-over-year, from $140.68M to $75.75M.
- What is the long-term trend for Ionis Pharmaceuticals's contract liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's contract liabilities has grown at a -26.3% compound annual growth rate (CAGR), from $424.05M to $92M.
- What does contract liabilities mean?
- The value of work or products owed to customers for which payment has already been collected.
- How do you interpret contract liabilities?
- Higher levels indicate a robust pipeline of committed work or partnership milestones that will be recognized as revenue in future periods.
- How does contract liabilities compare across companies?
- Highly comparable across companies utilizing licensing, royalty, or service-based revenue models.